Article Text

Download PDFPDF
Axonal Guillain–Barré syndrome is underestimated in Europe?
  1. S Kuwabara
  1. Department of Neurology, Graduate School of Medicine, Chiba University, Japan
  1. Correspondence to Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; kuwabara-s{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The concept of Guillain–Barré syndrome (GBS) largely changed in the 1990s, because acute motor axonal neuropathy (AMAN), an axonal subtype of GBS, was recognized. Neurophysiological, pathological and immunological observations have shown that GBS is currently divided into two major subtypes, acute inflammatory demyelinating polyneuropathy (AIDP; a classical demyelinating form) and AMAN.1

Before recognition of AMAN, the eponym GBS has been used interchangeably with AIDP, and it has been believed that in Europe and North America, GBS is usually caused by AIDP, which accounts for >90% of GBS cases.1 In contrast, a considerable number of GBS patients have AMAN in East Asia such as China …

View Full Text


  • Linked articles 208538.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles